Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis on Fico Stock & 2 other quality stocks

3 extracted signals · 3 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
02 Aug 2025, 15:34 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an analysis on Fico Stock & 2 other quality stocks
Source overview

AI-generated source summary

The analyst discusses three stocks near their 52-week lows: FICO, Chipotle, and Otis. The analyst notes that FICO is down 30% year-to-date despite good financial performance, mentioning rising revenues, bookings, earnings per share, and EBITDA. The stock's valuation is analyzed using estimates for earnings per share growth, set at 21% for 2026 and 24% for 2027 and then the analyst sets the growth to 20% for the subsequent years, stating $1147 as a good buy target. The video reviews Chipotle noting its financial decline in coop sales that has been dropping, and suggest wait for the $33 price point to consider a potential investment. Finally, a negative perspective is given to Otis Worldwide due to issues with China but positive in general the recommendation here is for $60 to be considered.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
3
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
3
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
3 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    3 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.0
Tracked signals
337
Historical success
33.6%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail